Brind.
From TMS Co., Ltd. signs licensing agreement with TME Pharma for NOX-A12

How could the TMS collaboration with TME Pharma affect Cognite's operational demands?

Possible What happens if… A possibility worth considering, not a forecast.

TMS's new biotech partnership may increase demands on Cognite's operational platform The exclusive negotiation agreement between TMS and TME Pharma centers on developing the flagship product NOX-A12. This partnership requires TMS to assume all ongoing costs related to NOX-A12, including operational costs, consultants, and patents, while enabling the restart of the GLORIA study. Since Cognite provides a platform that integrates with and supports TMS's operational systems, the increased complexity and scope of managing a biotech development program could alter the demands placed on Cognite's services.

Reported by 1 independent outlet Written Saturday
Effect
Mixed
How direct
Brind's reasoning
When
Within weeks
The story
No new developments lately

How it reaches Cognite

Reported by news outletsBrind's reasoning

Tap any step to see the evidence behind it.

The facts so far

As reported. Each one links to where it comes from.

  • TMS Co., Ltd. signed an exclusive negotiation agreement with TME Pharma on October 29.manilatimes.net
  • The collaboration aims to finalize a licensing agreement and further develop the flagship product NOX-A12.manilatimes.net
  • TMS will assume all ongoing costs related to NOX-A12, such as operational costs, consultants, and patents.manilatimes.net
  • The collaboration's next objective is to enable the restart of the GLORIA study.manilatimes.net

Why it matters

For Cognite, the partnership represents a potential shift in the type and scale of operational data and processes TMS requires its platform to handle. If the biotech development of NOX-A12 requires significantly more complex data tracking, resource allocation, or regulatory compliance management, Cognite's service usage and requirements for TMS could increase.

This collaboration is significant because TME Pharma is a biotech company that currently has negative equity (€2,61M as of June 2026) and no revenue (€27k, H1 2025). The partnership with TMS is a key move to secure stable, cash-generating opportunities and leverage tax loss carry forwards, making the operational demands placed on TMS's systems highly critical.

What we don't know yet

  • What specific operational systems within TMS will be utilized to manage the GLORIA study?
  • Will the increased complexity of the biotech partnership require new features or higher capacity from Cognite's platform?

What would change this answer

TME Pharma announces a successful restart of the GLORIA studyThis would confirm the operational scope and complexity of the partnership, likely increasing the certainty of higher demands on Cognite's platform.
TMS announces a reduction in its focus on biotech developmentThis would signal that the operational demands on Cognite's platform related to this specific partnership may remain stable or decrease.

Who else could feel it

Other possible ripples from the same event.

Reporting

Keep going

The full eventTMS Co., Ltd. signs licensing agreement with TME Pharma for NOX-A12 Everything aboutCognite

Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.